DrugPatentWatch Database Preview
LIPITOR Drug Profile
or, see our see our flat-rate plans
Which patents cover Lipitor, and what generic alternatives are available?
The generic ingredient in LIPITOR is atorvastatin calcium. There are sixty-one drug master file entries for this compound. Sixty-three suppliers are listed for this compound. Additional details are available on the atorvastatin calcium profile page.
Summary for LIPITOR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 14 |
| Bulk Api Vendors: | 63 |
| Clinical Trials: | 187 |
| Patent Applications: | 4,461 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for LIPITOR |
| DailyMed Link: | LIPITOR at DailyMed |
Pharmacology for LIPITOR
| Drug Class | HMG-CoA Reductase Inhibitor |
| Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Medical Subject Heading (MeSH) Categories for LIPITOR
Synonyms for LIPITOR
| (|AR,|AR)-2-(4-Fluorophenyl)-|A,|A-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Calcium Salt |
| (C33H34FN2O5)2.Ca |
| (R,R)-2-(4-Fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemicalcium salt |
| [R-(R*, R*)]-2-(4-fluorophenyl)-(beta), (delta)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, calcium salt (2:1) trihydrate |
| [R-(R*, R*)]-2-(4-fluorophenyl)-beta-, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid,calcium salt (2:1) trihydrate |
| 1108202-55-6 |
| 110862-48-1 (Parent) |
| 134523-03-8 |
| 1370463-14-1 |
| 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-,-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-, calcium salt (2:1), (R,R)- |
| 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, calcium salt (2:1), (R-(R*,R*))- |
| 1H-Pyrrole-1-heptanoic acid, beta,delta-dihydroxy-2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, calcium salt (2:1), (R-(R*,R*))- |
| 2C33H34FN2O5.Ca |
| 334757-04-9 |
| 4CA-0208 |
| AC1L1TZQ |
| ACT03226 |
| AK106989 |
| AKOS015896435 |
| AM90286 |
| AN-6412 |
| AOB6343 |
| AT-3134 |
| Atorvastan |
| ATORVASTATIN CALCIUM |
| Atorvastatin calcium [USAN:USP] |
| Atorvastatin calcium [USAN] |
| Atorvastatin calcium anhydorous |
| Atorvastatin calcium anhydrous |
| Atorvastatin calcium salt |
| Atorvastatin Hemicalcium |
| Atorvastatin hemicalcium salt |
| BB_SC-4721 |
| BC634906 |
| BDBM50442868 |
| C0GEJ5QCSO |
| CA0146 |
| calcium (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate |
| calcium (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate |
| calcium (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-heptanoate |
| Calcium (betaR,deltaR)-2-(p-fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoate (1:2) |
| calcium bis((3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate) |
| calcium bis{(3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate} |
| calcium;(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate |
| CAS-134523-03-8 |
| CHEBI:50686 |
| CHEMBL393220 |
| CI 981 |
| CI-981 |
| D00887 |
| DRG-0321 |
| DSSTox_CID_24303 |
| DSSTox_GSID_44303 |
| DSSTox_RID_80143 |
| DTXSID6044303 |
| FQCKMBLVYCEXJB-MNSAWQCASA-L |
| FT-0081085 |
| GS-3563 |
| HE307391 |
| I06-1867 |
| J-006551 |
| KB-270796 |
| Kolevas |
| KS-00000IS3 |
| Lipibec |
| LS-136974 |
| MFCD00899261 |
| MolPort-003-986-383 |
| NCGC00159458-03 |
| NCGC00159458-05 |
| NCGC00255845-01 |
| PD 134298-38A |
| Prevencor |
| Ranbaxy's Storvas |
| Rotacor |
| SC-76963 |
| SCHEMBL3832 |
| Sortis |
| Storvas |
| SYN3020 |
| Tahor |
| TL8000809 |
| Torvast |
| Tox21_111685 |
| Tox21_111685_1 |
| Tox21_302373 |
| UNII-C0GEJ5QCSO |
| VA10343 |
| YM 548 |
| YM-548 |
US Patents and Regulatory Information for LIPITOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-001 | Dec 17, 1996 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-004 | Apr 7, 2000 | AB | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-002 | Dec 17, 1996 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-003 | Dec 17, 1996 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
Expired US Patents for LIPITOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-001 | Dec 17, 1996 | ➤ Sign Up | ➤ Sign Up |
| Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-004 | Apr 7, 2000 | ➤ Sign Up | ➤ Sign Up |
| Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-003 | Dec 17, 1996 | ➤ Sign Up | ➤ Sign Up |
| Pfizer | LIPITOR | atorvastatin calcium | TABLET;ORAL | 020702-004 | Apr 7, 2000 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
or, see our see our flat-rate plans
